Bausch + Lomb Reports Q2 2025 Financial Results

Bausch + Lomb Corporation ( (BLCO) ) has released its Q2 earnings. Here is a breakdown of the information Bausch + Lomb Corporation presented to its investors.

Bausch + Lomb Corporation is a global leader in eye health, providing a wide range of products and services across three main segments: Vision Care, Pharmaceuticals, and Surgical. The company is a subsidiary of Bausch Health Companies Inc., with a significant presence on both the New York and Toronto Stock Exchanges under the ticker symbol ‘BLCO’.

In its latest earnings report for the quarter ending June 30, 2025, Bausch + Lomb reported revenues of $1.278 billion, a slight increase from the previous year’s $1.216 billion. However, the company faced a net loss of $58 million, which is an improvement from the $148 million loss reported in the same quarter last year. The company continues to navigate challenges such as foreign exchange impacts and increased interest expenses.

Key financial highlights include a 4.8% increase in product sales year-over-year, driven by strong performance in the Vision Care segment. Despite this growth, the company reported an operating loss of $11 million, primarily due to increased selling, general, and administrative expenses, as well as higher research and development costs.

Looking forward, Bausch + Lomb remains focused on its strategic initiatives, including the potential separation from Bausch Health Companies Inc. The company is evaluating various options to achieve this, which may include a distribution or sale transaction. Management is optimistic about the future, aiming to improve operational efficiencies and continue expanding its product offerings.

Overall, while Bausch + Lomb faces certain financial challenges, its commitment to innovation and strategic growth initiatives positions it well for future success in the global eye health market.